» Articles » PMID: 12539063

Epidemic Rift Valley Fever in Saudi Arabia: a Clinical Study of Severe Illness in Humans

Abstract

We describe the clinical patterns and case-fatality rate associated with severe Rift Valley fever (RVF) in patients who were admitted to the Gizan regional referral hospital during an outbreak of RVF in Saudi Arabia from September through November 2000. A total of 165 consecutive patients (136 men and 29 women) were prospectively studied; all were identified according to a strict case definition, were confirmed to have RVF by serologic testing, and were treated according to a predetermined protocol. The major clinical characteristics of RVF included a high frequency of hepatocellular failure in 124 patients (75.2%), acute renal failure in 68 patients (41.2%), and hemorrhagic manifestations in 32 patients (19.4%). Sixteen patients had retinitis and 7 patients had meningoencephalitis as late complications in the course of the disease. A total of 56 patients (33.9%) died. Hepatorenal failure, shock, and severe anemia were major factors associated with patient death.

Citing Articles

Comparative study of two Rift Valley fever virus field strains originating from Mauritania.

Chabert M, Lacote S, Marianneau P, Confort M, Aurine N, Pedarrieu A PLoS Negl Trop Dis. 2024; 18(12):e0012728.

PMID: 39652604 PMC: 11658707. DOI: 10.1371/journal.pntd.0012728.


Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis.

Connors K, Chapman N, McMillen C, Hoehl R, McGaughey J, Frey Z JCI Insight. 2024; 9(18.

PMID: 39088277 PMC: 11457859. DOI: 10.1172/jci.insight.180151.


The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis.

Griesman T, McMillen C, Negatu S, Hulahan J, Whig K, Dohnalova L PLoS Pathog. 2024; 20(6):e1012343.

PMID: 38935789 PMC: 11236204. DOI: 10.1371/journal.ppat.1012343.


Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.

Anywaine Z, Hansen C, Warimwe G, Abu-Baker Mustapher G, Nyakarahuka L, Balinandi S Virol J. 2024; 21(1):104.

PMID: 38702807 PMC: 11069174. DOI: 10.1186/s12985-024-02377-z.


Rift Valley Fever Virus Encephalitis: Viral and Host Determinants of Pathogenesis.

Wilson L, McElroy A Annu Rev Virol. 2024; 11(1):309-325.

PMID: 38635867 PMC: 11427164. DOI: 10.1146/annurev-virology-093022-011544.